慢性移植物抗宿主病(cGVHD)是异基因造血干细胞移植(allo-HSCT)后常见并发症。allo-HSCT前，对患者采取的移植物抗宿主病(GVHD)标准预防方案，可明显降低其急性GVHD(aGVHD)发生率，但是对降低cGVHD发生率效果不明显。现阶段以抗胸腺细胞球蛋白(ATG)为代表的GVHD预防方案，可以显著降低患者的cGVHD发生率及疾病严重程度。糖皮质激素是cGVHD的一线治疗药物，对于激素难治性cGVHH(SR-cGVHD)患者，目前已有多种新型二线药物，但尚无首选治疗方案。靶向cGVHD生物标志物的相关研究，将为其治疗提供新的方向。笔者拟就cGVHD的预防、治疗及生物标志物相关研究的新进展进行阐述。“,”Chronic graft versus host disease (cGVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Usage of prophylactic strategies of graft versus host disease (GVHD) before allo-HSCT significantly reduces the incidence of acute GVHD (aGVHD), but it plays a small role in reducing the incidence of cGVHD. At this stage, prophylactic drugs represented by antithymocyte globulin (ATG) can significantly reduce the incidence and severity of cGVHD. Corticosteroids are the first-line treatment of cGVHD. There are many new second-line drug choices for steroid-refractory cGVHD (SR-cGVHD) patients, but there is no first choice for it. The studies of targeted biomarkers of cGVHD will provide a new direction for the treatment of cGVHD in the future. This article summerizes the advances in the prevention, treatment and biomarkers of cGVHD.